Trial Profile
A Single-Arm, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 - 6 Infection (MAGELLAN-2)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Glecaprevir/pibrentasvir (Primary)
- Indications Hepatitis C
- Focus Registrational; Therapeutic Use
- Acronyms MAGELLAN-2
- Sponsors AbbVie
- 19 Apr 2018 Primary endpoint of percentage of participants with sustained virologic response 12 weeks post-treatment has been met, according to results published in the Hepatology.
- 19 Apr 2018 Results published in the Hepatology
- 10 Jul 2017 Status changed from active, no longer recruiting to completed.